AI-Driven Biotech METiS Pharma Secures $560M Series D Funding Ahead of Hong Kong IPO
METiS TechBio
AI-Driven Drug Formulation Developer
Note:This article does not constitute any investment opinions or recommendations., subject to official/company announcements;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted must obtain authorization.
PharmaCircleMonitoring shows:METiS TechBioRecentlyCompletedRMB 400 Million Series D Financing，Led by Beijing Medical and Health Industry Investment Fund and Daxing District Industrial Investment Fund. The financing will accelerate the advancement of several strategic priorities for METiS TechBio, including platform automation upgrades, progress in self-developed product pipelines, deepening international strategic cooperation, and the recruitment of high-end talent.
Founded inIn 2020METiS TechBioAsAn artificial intelligence (AI-driven nanomaterials innovation biotech company, focusing on utilizing targeted drug delivery and discovery technologies to help living organisms combat diseases and aging, regaining health and vitality., nowSuccessfully independently developedAI NanoBase Large Model and Three Core Solutions: AiLNP (AI Nucleic Acid Delivery System Design Platform), AiRNA (AI mRNA Sequence Design Platform), AiTEM (AI Small Molecule Formulation Design Platform).
https://test.metispharma.com/pipelines
Currently,METiS TechBio has achieved the capability to target key tissues and cells such as the liver, lungs, muscles, and immune cells using lipid nanoparticles (LNP).LNP) Precise Targeted Delivery Capability Achieves Breakthrough Progress in Multi-Organ and Multi-Tissue Targeted Delivery Challenges, providing drug development opportunities for cancer, metabolic system diseases, autoimmune diseases, neurodegenerative diseases, etc., and offering possibilities for organisms to resist aging at the organ level.
METiS TechBioThis time, it was also unveiled.OpenCGT Technology Platform, itsAiming to focus on the industry pain points of precise drug delivery, reduce development barriers and costs, incubate and empower breakthroughsThe R&D and clinical translation of CGT therapies help Beijing build a "new engine" for the life and health industry.
Relying onAI Nanodelivery Technology Innovation: METiS TechBio’s OpenCGT Platform Aims to Connect Beijing's Top University Research Strength, Large Triple-A Hospital Resources, and the Entire R&D Chain of CGT Innovative Pharmaceutical Companies. The platform has officially launched its first project, empowering AccuGen to develop a liver-targeted CRISPR gene-editing therapy based on mRNA-LNP.
Previous Investors
Rooted in Shanghai and radiating globally, PharmaCircle, as a strategic platform for the biopharmaceutical industry, is on a mission to "enable the boundless flow of intelligence and networks." It has built an empowering system that covers the entire pharmaceutical industry chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource linking, industry think tanks, and ecosystem communities—it is creating the infrastructure for the flow of pharmaceutical value in China.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises' leapfrog growth.
